<?xml version="1.0" encoding="UTF-8"?>
<p>Patients received glasdegib 100 mg orally, once daily in continuous 28‐day cycles. Patients received induction with glasdegib from day −3 in combination with intravenous daunorubicin 60 mg/m
 <sup>2</sup> (on days 1‐3) and continuous intravenous cytarabine 100 mg/m
 <sup>2</sup> (on days 1‐7). If required, a second induction cycle could be initiated at the same doses as early as day 21 of cycle 1. Patients achieving complete remission (CR) were eligible to receive consolidation therapy with 2‐4 cycles of cytarabine 1 g/m
 <sup>2</sup> twice daily on days 1, 3 and 5 of each cycle. Following consolidation, single‐agent glasdegib 100 mg administered daily continuously, as maintenance therapy, for a maximum of 6 cycles (1 cycle = 28 days) was permitted. Patients who completed the maximum number of treatment cycles and demonstrated clinical benefit were allowed to remain on therapy upon agreement between the investigator and sponsor.
</p>
